source
- FDA issues complete response letter rejecting ITM’s neuroendocrine tumor drug over manufacturing concernsThe U.S. Food and Drug Administration sent a complete response letter to ITM Isotopes Technologies, refusing approval of its lead candidate for gastroenteropancreatic neuroendocrine tumors because…
- Aspo Oyj announces upcoming leadership changes scheduled for August 10, 2026Aspo Oyj, a Finnish specialty chemicals company, issued a brief notice indicating that it will implement leadership transactions. The announcement specifies that the changes will take effect on Au…